Biotech Fluidics has announced the formation of Ventri Labs AB (VentriLabs), a new subsidiary established to leverage the breakthrough benefits of its patented gravity liquid pump technology for handling sensitive media.
The use of traditional mechanical pumps is known to have adverse effects on sensitive biological materials, limiting their use in bioprocessing, clinical and tissue engineering applications. Meticulously designed to handle sensitive media with care, VentriLabs' gravity-fed pump technology has been demonstrated to reduce the destructive mechanical and shear effects of pumping blood by up to 95% compared to commonly used peristaltic pumps.
This innovative technology is also more controllable, eliminating the pulsating effects inherent in peristaltic and membrane pumps. In filtration applications, this translates into increased efficiency and yields, resulting in a more cost-effective process for users.
“With multi-year funding from our parent company and a strong intellectual property portfolio, we are seeking collaboration partners and investors to accelerate our process and further develop our groundbreaking liquid pumping technology in laboratory, process and clinical applications,” said Dr. Robin Öz, CEO of VentriLabs.
Find out more online
